
Sept 24 - 26: The Americas
Sept 28 - 29: Europe & Africa
Oct 1 - 2: Asia & Oceania
Oct 2: Movie Night

Second Annual All-Community Virtual MSA Conference

OUR SPONSORS:

biohaven pharmaceuticals
Theravance Biopharma

AskBio

Medicines That Make a Difference®
Welcome to the Second Annual All-Community MSA Virtual Conference!

We are pleased that you are joining us. This conference is the result of many minds united in purpose. This year, we have assembled a remarkable meeting of MSA experts from all over the world: 42 presenters, 8 different languages and 5 continents are represented, the largest and most diverse MSA conference ever convened. We look forward to an educational, engaging and exciting week.

As a capstone to this extraordinary conference, we invite you to screen one or more of our recent documentary films: “Glimpses”, “A Day for Susana” and “MSA: The Ian Macindoe Story”!

Special Thanks to our 2021 Conference Committee & Friends:

Philip Fortier, Sandra Bettenhausen, Serge P., Monica Remartini, Wouter Peelaerts, Pratik Bhattacharya, Olivia Romano, Patrik Brundin, Sir Speedy Printing & Hubb.

Additional Thanks to All Our Affiliated Charities & Friends:

And A Big Thank You to Our Sponsors!!!
## Schedule of Speakers and Topics:

### Friday, 24th September

<table>
<thead>
<tr>
<th>Time</th>
<th>Language</th>
<th>Topic</th>
<th>Speaker/Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 AM</td>
<td>English</td>
<td>The Diagnosis of MSA</td>
<td>Anthony Lang, MD</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>English</td>
<td>Current Treatment Options</td>
<td>Edwin George, MD, PhD</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>English</td>
<td>Differential Diagnosis</td>
<td>Edwin George, MD, PhD</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>English</td>
<td>Clinical Q &amp; A (Session 1)</td>
<td>Katie Kompoliti, MD</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>English</td>
<td>Occupational Therapy and MSA</td>
<td>Mackenzie Carroll, OTD</td>
</tr>
<tr>
<td>2:15 PM</td>
<td>English</td>
<td>Connecting clinical researchers and patients between the western and eastern hemispheres to accelerate therapy access globally</td>
<td>Harsha Rajasimha, PhD</td>
</tr>
<tr>
<td>2:45 PM</td>
<td>English</td>
<td>Gene Therapy for MSA</td>
<td>Amber Van Laar, MD</td>
</tr>
<tr>
<td>3:15 PM</td>
<td>English</td>
<td>Meet the Expert: Q &amp; A follows after in AskBio Exhibit Booth</td>
<td>Amber Van Laar, MD</td>
</tr>
</tbody>
</table>

### Saturday, 25th September

<table>
<thead>
<tr>
<th>Time</th>
<th>Language</th>
<th>Topic</th>
<th>Speaker/Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00 AM</td>
<td>English</td>
<td>Clinical Research Update</td>
<td>Lucy Nordcliffe-Kaufmann, PhD</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>English</td>
<td>Experimental Animal Models of Multiple System Atrophy: The importance of α-synuclein strains and the MSA environment</td>
<td>Wouter Peelaerts, PhD</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>English</td>
<td>Current status and future directions in the genetics of MSA</td>
<td>Ziv Gan-Or, MD, PhD</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>English</td>
<td>The structural basis of the synucleinopathy Multiple System Atrophy, when pasta shape becomes handy</td>
<td>Ronald Melki, PhD</td>
</tr>
<tr>
<td>12:15 PM</td>
<td>English</td>
<td>Can infections be a trigger for MSA?</td>
<td>Patrik Brundin, MD, PhD</td>
</tr>
<tr>
<td>12:45 PM</td>
<td>English</td>
<td>Tracking α-synuclein pathology</td>
<td>Michael Henderson, PhD</td>
</tr>
<tr>
<td>Time</td>
<td>Language</td>
<td>Topic</td>
<td>Speaker/Moderator</td>
</tr>
<tr>
<td>--------------</td>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------</td>
</tr>
<tr>
<td>1:15 PM</td>
<td>English</td>
<td>Investigating the biological differences between Parkinson’s disease and multiple system atrophy</td>
<td>Sarah Holec, PhD</td>
</tr>
<tr>
<td>1:45 PM</td>
<td>English</td>
<td>Research Q &amp; A (Session 2)</td>
<td>Jeffrey Kordower, PhD</td>
</tr>
<tr>
<td>2:30 PM</td>
<td>French</td>
<td>Développement thérapeutique dans l’atrophie multisystématisée</td>
<td>Wassilios Meissner, MD, PhD</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>French</td>
<td>Présentation clinique et prise en charge des symptomes dans l’Atrophie MultiSystématisée</td>
<td>Anne Pavy-Le Traon, MD, PhD</td>
</tr>
</tbody>
</table>

### 26th September, Sunday

<table>
<thead>
<tr>
<th>Time (N.America)</th>
<th>Time (Europe)</th>
<th>Language</th>
<th>Topic</th>
<th>Speaker/Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 AM</td>
<td>8:00 AM</td>
<td>Spanish</td>
<td>Diagnóstico de AMS</td>
<td>Carlos Cosentino, MD</td>
</tr>
<tr>
<td>9:30 AM</td>
<td>8:30 AM</td>
<td>Spanish</td>
<td>Tratamiento de la Atrofia Multisistemática</td>
<td>Gabriel Jose Arango, MD</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>9:00 AM</td>
<td>Spanish</td>
<td>En busca de un buen tratamiento para MSA. Lecciones aprendidas y futuras perspectivas.</td>
<td>Enrique Urrea-Mendoza, MD</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>9:30 AM</td>
<td>Spanish</td>
<td>Clinical Q &amp; A (Session 3)</td>
<td>Gustavo Enrique Ospitia Rosero</td>
</tr>
<tr>
<td>1:00 PM</td>
<td>2:00 PM</td>
<td>Portuguese</td>
<td>Diagnóstico da Atrofia de Múltiplos Sistemas</td>
<td>Henrique Ferraz, MD</td>
</tr>
<tr>
<td>1:30 PM</td>
<td>2:30 PM</td>
<td>Portuguese</td>
<td>Atrofia de Múltiplos Sistemas - Tratamento</td>
<td>Francisco Cardoso, MD, PhD</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>3:00 PM</td>
<td>Portuguese</td>
<td>Clinical Q &amp; A (Session 4)</td>
<td>Lorena Brosseghini Barcelos</td>
</tr>
</tbody>
</table>

### 28th September, Tuesday

<table>
<thead>
<tr>
<th>Time (N.America)</th>
<th>Time (Europe)</th>
<th>Language</th>
<th>Topic</th>
<th>Speaker/Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td>2:00 PM</td>
<td>Italian</td>
<td>Diagnosi di AMS</td>
<td>Alessio Di Fonzo, MD, PhD</td>
</tr>
<tr>
<td>8:30 AM</td>
<td>2:30 PM</td>
<td>Italian</td>
<td>Trattamento dell’Atrofia Multisistemica</td>
<td>Maria Teresa Pellecchia, MD, PhD</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>3:00 PM</td>
<td>Italian</td>
<td>Clinical Q &amp; A (Session 5)</td>
<td>Monica Remartini</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>4:30 PM</td>
<td>English</td>
<td>Live Talk: New Diagnostic Criteria</td>
<td>Wassilios Meissner, MD, PhD</td>
</tr>
</tbody>
</table>
### 29th September, Wednesday

<table>
<thead>
<tr>
<th>Time (N.America)</th>
<th>Time (Europe)</th>
<th>Language</th>
<th>Topic</th>
<th>Speaker/ Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00 AM (EST)</td>
<td>10:00 AM (Poland)</td>
<td>Polish</td>
<td>Diagnostyka MSA (Diagnosis of MSA)</td>
<td>Gabriela Klodowska, MD, PhD</td>
</tr>
<tr>
<td>4:30 AM (EST)</td>
<td>11:30 AM (Moscow)</td>
<td>Russian</td>
<td>Диагностика мультисистемной атрофии (Diagnosis of multiple system atrophy)</td>
<td>Yury Seliverstov, MD, PhD</td>
</tr>
<tr>
<td>5:00 AM (EST)</td>
<td>12:00 AM (Moscow)</td>
<td>Russian</td>
<td>Множественная системная атрофия: терапия (Treatment of multiple system atrophy)</td>
<td>Cholpon Shambetova, MD</td>
</tr>
<tr>
<td>5:30 AM (EST)</td>
<td>12:30 AM (Moscow)</td>
<td>Russian</td>
<td>Надежда для пациентов с МСА: Последние исследования в сфере разработки лекарств (Hope for MSA: Latest Update)</td>
<td>Oybek Turgunkhujaev, MD</td>
</tr>
<tr>
<td>6:00 AM (EST)</td>
<td>1:00 PM (Moscow)</td>
<td>Russian</td>
<td>Clinical Q &amp; A (Session 7)</td>
<td>Marina Anikina, MD, PhD</td>
</tr>
</tbody>
</table>

### 1st October, Friday

<table>
<thead>
<tr>
<th>Time (N.America)</th>
<th>Time (Asia/AU)</th>
<th>Language</th>
<th>Topic</th>
<th>Speaker/ Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 PM (EST, 9/30)</td>
<td>10:30 AM (Sydney)</td>
<td>English</td>
<td>MSA Research</td>
<td>Glenda Halliday, PhD</td>
</tr>
<tr>
<td>10:00 PM (EST, 9/30)</td>
<td>10:00 AM (Taipei)</td>
<td>Chinese Traditional</td>
<td>Multiple system atrophy: Diagnosis, Treatment, and Research</td>
<td>Ming Che-Kuo, MD</td>
</tr>
<tr>
<td>11:00 PM (EST, 9/30)</td>
<td>12:00 PM (Tokyo)</td>
<td>English</td>
<td>Research to elucidate molecular basis of MSA</td>
<td>Shoji Tsuji, MD, PhD</td>
</tr>
</tbody>
</table>

### 2nd October, Friday: See next page of this booklet
Thank you for participating in this conference! If you are interested in helping us defeat MSA, please donate!

www.defeatmsa.org/donate-to-us
Representative Speakers

**Patrik Brundin, MD, PhD (United States)**
Dr. Brundin is the Van Andel Associate Director of Research Professor and the Director of the Center for Neurodegenerative Science. Dr. Brundin is one of the top cited researchers in the field of neuroscience with more than 350 publications on Parkinson’s disease and related topics. He has 35 years of experience studying neurodegenerative diseases. He was among the first to articulate the “prion-like” hypothesis, which describes how abnormal proteins spread from cell to cell in the brain, causing the cellular damage that perpetuates Parkinson’s, Multiple System Atrophy and Lewy Body Dementia.

**Francisco Cardoso, MD PhD FAAN (Brazil)**
Dr. Cardoso is a Professor of Internal Medicine Department (Neurology Service) at the Federal University of Minas Gerais (UFMG) in Belo Horizonte, Brazil. He is the founder and current Director of the UFMG Movement Disorders Clinic. He did his Neurology Residency at his current institution and a Movement Disorders Fellowship at the Baylor College of Medicine under the supervision of Joseph Jankovic MD. He is the President Elect of the International Parkinson’s Disease and Movement Disorders Society (MDS). His main areas of research are chорeas, particularly those of auto-immune origin; epidemiology of parkinsonism (he and his associates performed the first population-based study of prevalence of parkinsonism in Brazil) and the genetics of dystonia (one of the studies of his group led to the discovery of the DYT16 gene). He has authored more than 235 peer-reviewed papers and 120 book chapters.

**Carlos Cosentino, MD, PhD, FAAN (Peru)**
Dr. Cosentino received his medical degree from the Universidad Nacional Mayor de San Marcos in Lima-Peru. He completed his neurology residency training at the Instituto Nacional de Ciencias Neurologicas followed by a movement disorder fellowship at the Salpetriere Hospital. Since 1996, he has worked as a neurologist in the Neurodegenerative Diseases Department – Instituto Nacional de Ciencias Neurologicas and currently is the director of Movement Disorders. Dr. Cosentino is Associate Professor of Neurology at the Universidad Nacional Mayor de San Marcos and Senior lecturer on Neurology, with a concentration in movement disorders. He is a Fellow of the American Academy of Neurology (AAN). Dr. Cosentino was President of the Peruvian Neurological Society (2010-2012), served on the PAS-MDS Executive Committee and an Officer of the International Parkinson and Movement Disorders Society.

**Edwin George, MD, PhD (United States)**
Dr. George is the director of the Wayne State University Movement Disorders Center and is Associate Professor of Neurology at Wayne State University. He is a member and previous chairman of the Board of Directors and the Professional Advisory Board of the Michigan Parkinson’s Foundation. Dr. George’s research interests include clinical management of Parkinson’s disease, tremor, and dystonia, and he has been active in clinical trials of new medications for Parkinson’s disease and dystonia. He is also involved in research on measuring the impact of neurological disease on patient function. Dr. George’s laboratory research has focused on neuronal reaction to injury and neural regeneration. Dr. George has a Ph.D. in pharmacology, as well as an M.D., from Case Western Reserve University, and was a Grass Fellow in Neurophysiology at the Marine Biological Laboratory in Woods Hole, MA.
Glenda Halliday, PhD (Australia)
Professor Halliday is acclaimed internationally for her research on neurodegeneration, making major impacts on understanding disease progression, and her promotion of neuroscience, mentorship and contributions to research evaluation. From origins in comparative neuroanatomy, she established the Sydney Brain Bank and applied her expertise to clinicopathological correlations, revealing the anatomical, biochemical, molecular and genetic characteristics of several neurodegenerative diseases, particularly Parkinson’s disease and frontotemporal dementia. Her work has changed international diagnostic criteria, provided differentiating characteristics for neurological diseases and developed disease staging schemes. She has defined unique roles of certain genes and proteins, now being used to develop diagnostic protocols and potential therapies.

Anthony Lang, OC, MD, FAAN (Canada)
Dr. Lang is Professor and previous Director of the Division of Neurology at the University of Toronto where he holds the Jack Clark Chair for Parkinson’s Disease Research. He is the Director of the Edmond J. Safra Program in Parkinson’s Disease and the Morton and Gloria Shulman Movement Disorders Clinic and holds the Lily Safra Chair in Movement Disorders at the Toronto Western Hospital, University Health Network. He has published over 750 peer-reviewed papers and is one of the most highly cited investigators in the field of Movement Disorders. Among his awards and distinctions he was appointed as an Officer of the Order of Canada in 2010; in 2011 he was elected a Fellow of both the Canadian Academy of Health Sciences and the Royal Society of Canada; in 2014 he was elected by the International Parkinson and Movement Disorder Society (MDS) as an Honorary Member “in recognition of his extraordinary contribution to the field of Movement Disorders”; and in 2017 he was the recipient of the first MDS Pan-American Section Leadership Award. In 2018, he received the Weston Brain Institute International Outstanding Achievement Award for work in accelerating the development of therapeutics for neurodegenerative diseases of aging and in 2020 he received the Dean’s Lifetime Achievement Award for global impact from the University of Toronto. Dr. Lang serves on the research advisory committees for both Defeat MSA Alliance (US) and MSA United International Consortium.

Wassilios Meissner, MD, PhD (France)
Professor Meissner is a neurologist, with subspecialty expertise in Movement Disorders and particular interest in Parkinson’s disease (PD) and atypical parkinsonian disorders such as Multiple System Atrophy (MSA) and Progressive Supranuclear Palsy (PSP). He is affiliated with the University of Bordeaux where he has been a professor of Neurology since 2012. He is the director of the PD Expert Centre of Bordeaux and co-chairs the French Reference Centre for MSA. His research focuses on biological and clinical markers of disease progression in PD and MSA, as well as the development of new preclinical models and treatments for PD and MSA in a translational approach. His current research activities include work with two innovative vaccines directed against alpha-synuclein in patients with MSA and coordination with the European ARTEMIS research consortium.

For more detailed speaker profiles and for the complete list of conference speakers please visit the Speaker Directory on defeatmsa2021.hubb.me
Defeat MSA Alliance’s Mission:
Realizing that much of the current attention is focused on more widely known diseases, Multiple System Atrophy is often overlooked. MSA patients are confronted with a dim prognosis and left with few options. Defeat MSA Alliance is an inclusive US based 501(c)(3) charity that aspires to balance efforts to support patients, educate medical professionals, raise public awareness, nurture promising research and advocate for the MSA community. Staffed entirely by volunteers, Defeat MSA Alliance specifically aims to achieve a five-fold mission:

- To build a world that truly supports people with MSA
- To foster better medical education about MSA
- To increase public awareness about living with MSA
- To cultivate promising research into treatments and slowing MSA
- To advance the interests of all people challenged by MSA.

Defeat MSA Alliance invites all other like-minded individuals, around the world, to join us in this noble fight: to speak for those who cannot, with one mind, one heart and one voice: to defeat MSA forever!

Defeat MSA Alliance
29924 Jefferson Avenue
Saint Clair Shores, Michigan 48082

TOLL FREE (NORTH AMERICA):
(855) KICK-MSA (855 542-5672)
INFO@DEFEATMSA.ORG
www.defeatMSA.org | www.MSAunited.org

Defeat MSA Alliance is a US based 501(c)(3) charity that aspires to balance efforts to support patients, educate medical professionals, raise public awareness and nurture promising research.

Medical Treatment Disclaimer:
The purpose of this conference is to provide information about the diagnosis, known treatments and current research about Multiple System Atrophy. It is for informational purposes only. All conference attendees and anyone that may view the conference videos are advised to consult with their health providers first before taking any steps. For any questions pertaining to diagnosis or treatment, please consult with your health provider.

©2021 Defeat MSA Alliance. The Defeat MSA Alliance name and logo are trademarks of the Defeat MSA Alliance. The media capture or recording of this conference by others not associated with Defeat MSA Alliance is strictly prohibited unless written permission is granted by Defeat MSA Alliance. A recording of the entire conference will be made available by Defeat MSA Alliance after the meeting. All other legal rights, trademarks and permissions are the property of their respective holders. Participation in the conference implies consent for Defeat MSA Alliance to capture the event’s videos and images for future use.
– ADDITIONAL DISCLAIMERS –

Personal Views Disclaimer:
The views expressed in this virtual MSA conference are those of the speakers and attendees. They do not purport to reflect the opinions, views or official policies of Defeat MSA Alliance. Defeat MSA Alliance is providing this free conference and the live streaming film as a support and educational service to the MSA community.

Intellectual Property Disclaimer:
Please read this disclaimer carefully before attending this conference hosted by Defeat MSA Alliance. The content broadcasted in this conference is the intellectual property of the speakers and Defeat MSA Alliance. You may not record, reuse, republish, or reprint such content without our written consent. All information posted is merely for educational and informational purposes. It is not intended as a substitute for professional advice. Should you decide to act upon any information on this website, you do so at your own risk. While the information offered in the conference and on various associated websites have been verified to the best of our abilities, we cannot guarantee that there are no mistakes or errors. We reserve the right to change this policy at any given time, of which you will be promptly updated.

Defeat MSA remembers all those we have lost to MSA …

and we continue to fight for and with all those who live each day with MSA!

Join Our Fight: www.DefeatMSA.org

FOLLOW US ON SOCIAL MEDIA: MSA Shoe Instagram Twitter “Where is the MSA Shoe?” Facebook